Indegene Ltd (INDGN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Indegene Ltd (INDGN) has a cash flow conversion efficiency ratio of 0.071x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs2.03 Billion ≈ $21.93 Million USD) by net assets (Rs28.66 Billion ≈ $309.90 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Indegene Ltd (INDGN) market capitalisation for the company's overall valuation and market capitalisation.
Indegene Ltd - Cash Flow Conversion Efficiency Trend (2020–2026)
This chart illustrates how Indegene Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Indegene Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Indegene Ltd ranked by their cash flow conversion efficiency. Explore earnings quality score of Indegene Ltd to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Top Glove Corporation Bhd
KLSE:7113
|
0.022x |
|
Kemper Corporation
NYSE:KMPR
|
-0.012x |
|
SL Corp
KO:005850
|
0.023x |
|
Permian Basin Royalty Trust
NYSE:PBT
|
88.414x |
|
Emlak Konut Gayrimenkul Yatirim Ortakligi AS
IS:EKGYO
|
-0.270x |
|
Central Securities Corporation
NYSE MKT:CET
|
0.006x |
|
General American Investors Closed Fund
NYSE:GAM
|
-0.281x |
|
DUERR AG UNSP.ADR 1/5
F:DUEB
|
0.117x |
Annual Cash Flow Conversion Efficiency for Indegene Ltd (2020–2026)
The table below shows the annual cash flow conversion efficiency of Indegene Ltd from 2020 to 2026. View Indegene Ltd stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-03-31 | Rs31.39 Billion ≈ $339.44 Million |
Rs6.63 Billion ≈ $71.74 Million |
0.211x | +25.10% |
| 2025-03-31 | Rs26.16 Billion ≈ $282.87 Million |
Rs4.42 Billion ≈ $47.79 Million |
0.169x | -52.44% |
| 2024-03-31 | Rs14.29 Billion ≈ $154.55 Million |
Rs5.08 Billion ≈ $54.91 Million |
0.355x | +190.20% |
| 2023-03-31 | Rs10.64 Billion ≈ $115.04 Million |
Rs1.30 Billion ≈ $14.08 Million |
0.122x | -68.52% |
| 2022-03-31 | Rs7.64 Billion ≈ $82.61 Million |
Rs2.97 Billion ≈ $32.12 Million |
0.389x | -24.71% |
| 2021-03-31 | Rs3.33 Billion ≈ $36.02 Million |
Rs1.72 Billion ≈ $18.60 Million |
0.516x | +136.17% |
| 2020-03-31 | Rs-155.98 Million ≈ $-1.69 Million |
Rs222.73 Million ≈ $2.41 Million |
-1.428x | -- |
About Indegene Ltd
Indegene Limited operates as a digital-first life sciences commercialization company in India, the United States, Europe, and internationally. It operates through three segments: Enterprise Medical Solutions, Enterprise Commercial Solutions, Omnichannel Activation & Others. The company develops biotech and medical device for biopharmaceutical, emerging biotech, and medical device companies. It al… Read more